CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 25 enrolled
Drug / intervention
13-valent conjugate pneumococcal vaccinebiological
Likely dose
13-valent conjugate pneumococcal vaccine 0.5mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01974817
NCT01974817Phase 4Completed
CompareCT.gov

Streptococcus Pneumoniae Colonization and Immunogenicity of 13-valent Conjugate Pneumococcal Vaccine in Patients 50 Years or Older With End Stage Renal Disease on Dialysis.

Michigan State University·interventional·Posted Nov 4, 2013·Updated Nov 17, 2016

In Brief

A Phase 4 clinical trial evaluating 13-valent conjugate pneumococcal vaccine for End Stage Renal Disease. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The purpose of the study is to determine the response of 13-valent conjugate pneumococcal vaccine in patients 50 years or older with end stage renal disease on dialysis. The study will also try to determine Streptococcus pneumoniae colonization in patients 50 years or older with end stage renal disease on dialysis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Disease
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 4, 2013
Enrollment StartMay 1, 2013
Primary CompletionDec 1, 2013
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.7 years ago

Interventions

13-valent conjugate pneumococcal vaccinebiological

0.5ml IM for one dose